Posted by Michael Wonder on 24 Jun 2021
FDA accepts application for Genentech’s port delivery system with ranibizumab for treatment of wet age related macular degeneration
24 June 2021 - If approved, PDS would be the first and only eye implant with continuous drug delivery that offers people living with wet AMD an alternative to frequent eye injections.
Genentech today announced that the U.S. FDA has accepted the company’s biologics license application, under priority review, for port delivery system with ranibizumab for the treatment of wet, or neovascular, age-related macular degeneration.
